<DOC>
	<DOCNO>NCT01516515</DOCNO>
	<brief_summary>This Phase II study evaluate efficacy SR-T100 gel 2.3 % SM Solanum undatum plant extract patient Actinic Keratosis ( AK ) .</brief_summary>
	<brief_title>Efficacy Safety Phase II Study SR-T100 Treat Actinic Keratosis</brief_title>
	<detailed_description />
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<criteria>1 . Male female ; age ≥ 18 year old . 2 . Patient accepts enter study signing write informed consent . 3 . Patient 4 8 clinically diagnose , discrete , nonhyperkeratotic , nonhypertrophic AK , locate without contiguous 25cm2 area . 4 . Patient allow biopsy perform select lesion . 5 . Patient agree apply study medication prescribe treatment area occlusive dressing least 20 hour per day . 6 . Patient agree photograph take selected lesion use part study data package . 7 . Patient good general health condition ( performance status ≤ 2 Eastern Cooperative Oncology Group ( ECOG ) . 8 . Sexually active female patient childbearing potential must take reliable contraception method ( ) participation study . 1 . Patient recurrent invasive squamous cell carcinoma ( SCC ) . 2 . Patient grossly suspicious inflame lymph node physical examination . 3 . Patient evidence clinically significant unstable medical condition . 4 . Patient skin condition treatment area may make bad treatment . 5 . Patient currently use use treatment area ( ) OTC retinol product , corticosteroid , cryosurgery , curettage , 5fluorouracil ( 5FU ) , imiquimod , topical diclofenac , retinoids , topical AK treatment ( laser abrasion , dermabrasion , glycolic acid , chemical peel ) 28 day prior screen visit . 6 . Patient receive systemic cancer chemotherapy immunosuppressant ; target evaluation area psoralen plus UVA therapy , UVB therapy treat 6 month prior screen visit . 7 . Patient currently use use prednisone and/or prednisolone ( ≥ 10 mg equivalent ) 2 week continuously within 12 week prior randomization visit . 8 . Engaging activity involve excessive prolonged exposure sunlight . 9 . History allergy sensitivity relate compound component investigational product formulation . 10 . Woman pregnant , lactate plan become pregnant study . 11 . Patient use investigational drug within 8 week prior screen visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Actinic Keratosis</keyword>
	<keyword>AK</keyword>
</DOC>